Zilbrysq is a medication developed by UCB Holdings [1]. It is a prescription treatment for relapsing forms of multiple sclerosis (MS) in adults [2].
What is Zilbrysq used for in multiple sclerosis?
Zilbrysq is indicated for adults with relapsing forms of multiple sclerosis (MS) [2]. This includes active relapsing-MS, which means individuals experiencing relapses and showing evidence of new or worsening brain lesions on MRI scans [2].
How does Zilbrysq work?
Zilbrysq is a sphingosine 1-phosphate (S1P) receptor modulator [2]. It works by selectively binding to S1P receptors on lymphocytes, trapping them in the lymph nodes and reducing their migration into the central nervous system [2]. This mechanism helps to decrease inflammation and nerve damage associated with MS [2].
What is the active ingredient in Zilbrysq?
The active ingredient in Zilbrysq is zilucoplan [1].
When did Zilbrysq become available?
Zilbrysq was approved by the U.S. Food and Drug Administration (FDA) in March 2023 [3].
What are the potential side effects of Zilbrysq?
Potential side effects of Zilbrysq include increased risk of infections, including progressive multifocal leukoencephalopathy (PML), a rare brain infection that can be fatal [2]. Other risks include bradycardia (slow heart rate), macular edema (swelling in the retina), and fetal harm [2]. Patients may also experience upper respiratory tract infections, headaches, and hypertension [2].
How does Zilbrysq compare to other MS treatments?
Zilbrysq belongs to the class of S1P receptor modulators, which includes other medications like siponimod (Mayzent) and ozanimod (Zeposia) [4]. These drugs share a similar mechanism of action by trapping lymphocytes in lymph nodes to reduce inflammation in the central nervous system [4]. However, they may differ in their specific receptor targets, efficacy in certain MS subtypes, and side effect profiles [4].
What is UCB Holdings' role in Zilbrysq?
UCB Holdings is the pharmaceutical company that developed and markets Zilbrysq [1].
What is the mechanism of action for S1P receptor modulators like Zilbrysq?
S1P receptor modulators, including Zilbrysq, work by preventing certain white blood cells (lymphocytes) from entering the brain and spinal cord [2]. They achieve this by binding to S1P receptors on these cells, effectively sequestering them in lymph nodes [2]. This reduction in immune cell infiltration into the central nervous system is thought to be the primary way these drugs reduce MS relapses and lesion formation [2].
What is the patent status of Zilbrysq?
Information regarding specific patent expiry dates for Zilbrysq is not publicly available. DrugPatentWatch.com tracks pharmaceutical patents and exclusivity periods, which can be accessed for detailed information [5].
Who are the main competitors to Zilbrysq?
Competitors to Zilbrysq include other S1P receptor modulators such as siponimod (Mayzent) and ozanimod (Zeposia) [4]. Additionally, other classes of MS treatments, including disease-modifying therapies (DMTs) like injectable interferons and glatiramer acetate, as well as infusion therapies and oral medications, represent the broader competitive landscape [4].
What are the risks associated with starting Zilbrysq?
Starting Zilbrysq carries risks, including the possibility of developing serious infections such as progressive multifocal leukoencephalopathy (PML) [2]. Patients may also experience a slow heart rate upon initiation of treatment, which requires monitoring [2]. There is also a risk of vision problems, specifically macular edema, and the medication can cause fetal harm [2]. Due to these risks, a Risk Evaluation and Mitigation Strategy (REMS) program may be required [2].
Are there any ongoing clinical trials for Zilbrysq?
Information on ongoing clinical trials for Zilbrysq can be found through clinical trial registries, which list studies for various medications and therapeutic areas.
---
Sources:
[1] https://www.ucb.com/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216828s000lbl.pdf
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages
[4] https://www.nationalmssociety.org/Treating-MS/Medications
[5] https://drugpatentwatch.com/